From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
2-(Dimethylamino)-2-phenylbutyl 3,4,5-trimethoxybenzoate
CAS Number 39133-31-8
ATC code A03AA05 (WHO)
PubChem CID 5573
Chemical data
Formula C22H29NO5
Molar mass 387.47 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Trimebutine is a drug with antimuscarinic and weak mu opioid agonist effects.[1] The maleic acid salt of trimebutine is marketed under the trademark of Debridat, Recutin, or Polybutin [2] for treatment of irritable bowel syndrome and other gastrointestinal disorders. The major product from drug metabolism of trimebutine in human beings is nor-trimebutine,[3] which comes from removal of one of the methyl groups attached to nitrogen. Both Trimebutine and its metabolite are commercially available.


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />



  1. Kaneto H, Takahashi M, Watanabe J. The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies. Journal of Pharmacobiodynamics. 1990 Jul;13(7):448-53. PMID 1963196
  2. Ok Hwa Jhee, Yun Sik Lee, Leslie M. Shaw, Yong Cheol Jeon, Min Ho Lee, Seung Hoon Lee and Ju Seop Kang The Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin™ and Polybutin™) in healthy male volunteers using the LC–MS/MS method. Clinica Chimica Acta. 2007 Jan;375(1-2):69-75. PMID 16854404
  3. F.J. Roman, S. Lanet, J. Hamon, G. Brunelle, A. Maurin, P. Champeroux, S. Richard, N. Alessandri, and M. Gola Pharmacological Properties of Trimebutine and N-Monodesmethyltrimebutine. The Journal of Pharmacology and Experimental Therapeutics 1999;289:1391-1397. PMID 10336531